A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted

NCT05983874 · clinicaltrials.gov ↗
PHASE1
Phase
ENROLLING_BY_INVITATION
Status
8
Enrollment
NETWORK
Sponsor class

Conditions

Interventions

Sponsor

International AIDS Vaccine Initiative

Collaborators